Clinical trial
Study Effect of VIA-2291 on Vascular Inflammation
NCT00358826 · Tallikut Pharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT00358826 |
|---|---|
| Title | Study Effect of VIA-2291 on Vascular Inflammation |
| Official title | Clinical Study Protocol No. VIA-2291-01, A Phase 2 Randomized, Double-blind, Parallel-group, Placebo-controlled, Dose-ranging Study of the Effect of VIA-2291 on Vascular Inflammation in Patients After an Acute Coronary Syndrome Event |
| Lead sponsor | Tallikut Pharmaceuticals, Inc., Industry |
| Collaborators | Montreal Heart Institute |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Coronary Artery Disease |
| Intervention type | Drug |
| Interventions | VIA-2291, Placebo |
| Enrollment | 191 |
| Start date | Jul 1, 2006 |
| Primary completion | Aug 1, 2008 |
| Completion | Sep 1, 2008 |
| First posted | Aug 1, 2006 |
| Last update posted | Jul 23, 2012 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: